Tradestie Institutional Equity Comparison Engine
CLSD vs ITRM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ITRM Overall Edge
ITRM Captures Institutional Edge (1โ1 Pillars ยท 3โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Iterum Therapeutics plc Ordinary Share (ITRM) driven by superior Growth & Margin while CLSD counters with relative strength in Momentum & Technical. Fundamentally, CLSD trades at N/M Forward P/E with -3502.5% operating margin (-80.6% YoY revenue) versus ITRM at N/M Forward P/E and -1982.3% operating margin (-100.0% YoY). In options structure, CLSD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ITRM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CLSD N/M vs ITRM N/M Fwd P/E
Growth & Margin Winner
ITRM
Op Margin -3502.5% vs -1982.3% ยท YoY -80.6% vs -100.0%
Momentum & Technical Winner
CLSD
1Y -97.5% vs -97.6% ยท 52W Pos 1% vs 0%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CLSD
NASDAQ
Clearside Biomedical, Inc. Common Stock
Pharmaceutical Preparations
$0.41
-26.96% 1D
Market Cap
$2.9M
1M Return
-88.86%
1Y Return
-97.47%
Forward P/E
N/M
Unified AI Score
43.3 / 100
HOLD
Tech 40.0
Fund 43.0
Flow 50.0
Mom 40.0
ITRM
NASDAQ
Iterum Therapeutics plc Ordinary Share
Pharmaceutical Preparations
$0.03
-57.39% 1D
Market Cap
$3.8M
1M Return
-89.38%
1Y Return
-97.62%
Forward P/E
N/M
Unified AI Score
50.5 / 100
HOLD
Tech 40.0
Fund 52.0
Flow 50.0
Mom 75.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CLSD -97.47%
ITRM -97.62%
Spread: +33.63 pp (ITRM Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CLSD TTM Op. Margin: -3502.5%
ITRM TTM Op. Margin: -1982.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLSD vs ITRM. Trailing 12-month operating profitability (CLSD -3502.5% vs ITRM -1982.3%) and valuation multiples (CLSD N/M vs ITRM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CLSD | ITRM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.9M | $3.8M | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -80.6% | -100.0% | Higher Growth | CLSD |
| Operating Margin (TTM) Profitability | -3502.5% | -1982.3% | Higher Margin | ITRM |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -1310.0% | -555.7% | Higher ROE | ITRM |
| 52-Week Range Position Momentum | 1% ($0โ$17) | 0% ($0โ$1) | Stronger Trend | Tie |
| Beta / 30D Volatility Risk Regime | 2.24ฮฒ ยท 269% Vol | 1.61ฮฒ ยท 508% Vol | Lower Realized Risk | CLSD |
| Unified Institutional Score Composite Signal | 43.3 / 100 (HOLD) | 50.5 / 100 (HOLD) | Higher Composite | ITRM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CLSD vs ITRM Buy Guide
CLSD
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ITRM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CLSD nor ITRM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.